文献速递慢性肾脏病水电解质与酸碱

SAPPHIRE 研究的基本原理、设计、人口学和基线特征:维立奴拉德联合别嘌醇治疗慢性肾脏病合并高尿酸血症的随机对照2b期研究

Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia.
PubMed 文献 · Nephrol Dial Transplant · 2022-01-01

SAPPHIRE 是一项随机、安慰剂对照2b期研究,计划纳入约725例CKD、eGFR≥25 mL/min/1.73 m2、UACR 30-5000 mg/g且sUA≥6.0 mg/dL的成人患者,按1:1:1:1:1随机接受不同剂量维立奴拉德联合别嘌醇、别嘌醇单药或安慰剂治疗,主要终点为6个月时UACR较基线的变化,旨在评估联合治疗对白蛋白尿和eGFR斜率的影响及肾脏保护作用。

要点

  • 维立奴拉德联合别嘌醇可能降低CKD合并高尿酸血症患者的白蛋白尿。
  • 研究主要终点为6个月UACR较基线变化,次要终点包括eGFR和sUA变化。
  • 纳入标准包括eGFR≥25 mL/min/1.73 m2、UACR 30-5000 mg/g、sUA≥6.0 mg/dL。

核心结论

  • SAPPHIRE研究将评估维立奴拉德联合别嘌醇对CKD合并高尿酸血症患者肾功能的影响,以及该联合是否在标准治疗之外提供肾脏保护。

研究设计与样本

  • 随机、安慰剂对照2b期研究,计划纳入约725例成人CKD合并高尿酸血症患者,按1:1:1:1:1随机分组。
  • 治疗包括8周剂量滴定期和12个月治疗期,3 mg维立奴拉德联合别嘌醇组部分患者在第9个月剂量增至24 mg。

主要发现

  • 2a期研究(NCT03118739)中,维立奴拉德联合非布司他在2型糖尿病、高尿酸血症和蛋白尿患者中12周降低UACR 39%(90% CI 4-62%)。

关键数值与推荐

  • 纳入标准:年龄≥18岁,CKD,eGFR≥25 mL/min/1.73 m2,UACR 30-5000 mg/g,sUA≥6.0 mg/dL。
  • 主要疗效终点为6个月时UACR较基线的变化;次要终点包括6和12个月时UACR、eGFR和sUA较基线的变化。

临床怎么用

  • 该研究结果可能为CKD合并高尿酸血症患者提供超越标准治疗的肾脏保护策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Verinurad is a human uric acid (UA) transporter (URAT1) inhibitor known to decrease serum UA (sUA) levels and that may reduce albuminuria. In a Phase 2a study (NCT03118739), treatment with verinurad + febuxostat lowered urine albumin-to-creatinine ratio (UACR) at 12 weeks by 39% (90% confidence interval 4-62%) among patients with Type 2 diabetes mellitus, hyperuricaemia and albuminuria. The Phase 2b, randomized, placebo-controlled Study of verinurAd and alloPurinol in Patients with cHronic kIdney disease and hyperuRicaEmia (SAPPHIRE; NCT03990363) will examine the effect of verinurad + allopurinol on albuminuria and estimated glomerular filtration rate (eGFR) slope among patients with chronic kidney disease (CKD) and hyperuricaemia. METHODS: Adults (≥18 years of age) with CKD, eGFR ≥25 mL/min/1.73 m2, UACR 30-5000 mg/g and sUA ≥6.0 mg/dL will be enrolled. Approximately 725 patients will be randomized 1:1:1:1:1 to 12, 7.5 or 3 mg verinurad + allopurinol, allopurinol or placebo. An 8-week dose-titration period will precede a 12-month treatment period; verinurad dose will be increased to 24 mg at Month 9 in a subset of patients in the 3 mg verinurad + allopurinol arm. The primary efficacy endpoint the is change from baseline in UACR at 6 months. Secondary efficacy endpoints include changes in UACR, eGFR and sUA from baseline at 6 and 12 months. CONCLUSIONS: This study will assess the combined clinical effect of verinurad + allopurinol on kidney function in patients with CKD, hyperuricaemia and albuminuria, and whether this combination confers renoprotection beyond standard-of-care.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Heerspink HJL, Stack AG, Terkeltaub R, et al. Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia. Nephrol Dial Transplant. 2022. PMID: 34383954. doi:10.1093/ndt/gfab237

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。